Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BIOTRONIK Home Monitoring® Reduces Inappropriate ICD Shocks by 52%

Published: Friday, December 21, 2012
Last Updated: Friday, December 21, 2012
Bookmark and Share
ECOST trial results published in European Heart Journal.

BIOTRONIK has announced that the European Heart Journal has published the clinical results of the ECOST trial (Effectiveness and Cost Of ICD Follow-Up Schedule with Telecardiology).

The randomized controlled study evaluated the safety and efficacy of BIOTRONIK Home Monitoring® compared with standard in-office follow-up visits for patients with implantable cardioverter-defibrillators (ICDs).

Results from ECOST provide pioneering scientific evidence that continuous remote monitoring with BIOTRONIK Home Monitoring® reduces inappropriate shocks, may improve battery longevity in long-term follow-up of patients implanted with an ICD and is as safe as, sometimes even safer than standard in-office follow-ups. This outcome is consistent with previous findings from studies such as the landmark TRUST trial.

ECOST is a prospective multicenter clinical trial designed to examine the safety and efficacy of remote monitoring of ICD patients with BIOTRONIK Home Monitoring® over 27 months.

The study analyzed 433 patients from 43 sites throughout France who were randomly assigned to home monitoring follow-up or standard in-office care.

The 221 home monitoring patients (the active group) were seen in the ambulatory department once per year, unless home monitoring reported a technical or clinical event requiring an in-office visit. The 212 control group patients underwent in-office visits every six months.

During a two-year period, the overall number of delivered shocks in the home monitoring group were 71% lower than in the control group-a significant decrease.

Furthermore, the proportion of patients who received inappropriate shocks was 52% lower in the home monitoring group than in the control group.

While some remote monitoring technologies can drain the device battery in the long term, daily BIOTRONIK Home Monitoring® retains ICD battery life: ECOST showed a 76% reduction in the number of capacitor charges for the BIOTRONIK Home Monitoring® group (499 vs. 2081), resulting in extended device longevity.

“The ECOST trial results prove BIOTRONIK Home Monitoring® reduces inappropriate shocks in patients and also positively extends the ICD’s battery longevity,” said Professor Salem Kacet, principal investigator of the ECOST study.

Professor Kacet continued, “This advanced technology is very important for the observation of arrhythmias and early adaptation of ICD therapy. Patients benefit from the reduced risk of inappropriate shocks-which can be a very unpleasant experience-and need ICD replacement less frequently.”

“Developing safe, innovative, effective therapies to improve patient health is BIOTRONIK’s number one priority,” said Christoph Böhmer, President International of BIOTRONIK.

Böhmer continued, “By conducting landmark trials like ECOST, we are providing definitive answers to questions and challenges physicians face in their practices. In addition, we are making significant contributions to the field of cardiac rhythm therapy research. BIOTRONIK Home Monitoring® enhances the patient’s quality of life and simplifies patient treatment.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Approves First Single-Lead ICD with Atrial Sensing
BIOTRONIK’s Lumax DX system could help the 50,000 patients each year who may benefit from atrial sensing, without pacing indication.
Tuesday, September 17, 2013
BIOTRONIK Orsiro Hybrid DES Lives Up to Abbott’s XIENCE PRIME™
Positive 9 month results from BIOFLOW-II clinical trial and 12 month results from BIOFLOW-III registry presented at EuroPCR congress.
Tuesday, July 09, 2013
BIOTRONIK Announces 12-Month Results from 4EVER Study
Results show strong evidence of benefits for lower limb intervention when using Pulsar stents.
Monday, November 19, 2012
First CRT-D Patient Enrolled in the EuroEco ICD/CRT-D Trial
Study to assess the economic effects of BIOTRONIK Home Monitoring®.
Tuesday, July 24, 2012
Large-Scale BIOTRONIK SPIRIT-ICD Study Enrollment Complete
SPIRIT-ICD study explores benefits of intensified diagnostic follow-up and timely therapeutic intervention for high-risk patient group.
Monday, July 09, 2012
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!